Israeli pharmaceutical company Compugen, which develops genomics-based drug and diagnostic discovery tools, has sold its controlling stake in its subsidiary Keddem Bioscience. The acquisition, estimated to worth $15 million, was made by a privately owned US based investment company.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments